{"id":"W3176532045","doi":"10.1016/s0140-6736(21)00933-8","title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1664,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Chimeric antigen receptor; Antigen; Refractory (planetary science); Medicine; Open label; Multiple myeloma; Receptor; Immunology; Cell; Immunotherapy; Cancer research; Biology; Internal medicine; Immune system; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}